

ESMO 2019 Industry Satellite Symposium

From triple-negative to Dx-positive breast cancer: *Perspectives and experience with cancer immunotherapy for patients with metastatic triple-negative disease*

Monday, 30 September 2019, 13:00–14:30

Pamplona Auditorium, Hall 2, Fira Gran Via, Barcelona, Spain

A light lunch will be provided

Programme

13:00–13:05	Introduction: TNBC landscape and recent approvals of new therapeutics David Miles, UK
13:05–13:20	Overview of current CIT treatments and biomarkers in mTNBC Peter Schmid, UK & Leisha Emens, USA
13:20–13:35	Why should you talk to your pathologist about PD-L1 testing in mTNBC? Leisha Emens & Giuseppe Viale, Italy
13:35–13:55	Treatment decisions in clinical practice Carlos Barrios, Brazil
13:55–14:10	Future evolution of mTNBC treatment Peter Schmid
14:10–14:25	Question & answer session All
14:25–14:30	Wrap-up and summary David Miles

